LSU’s Pennington Biomedical Research Center will be the site for the Phase I trial of a new treatment for cocaine, smoking and methamphetamine addiction.
The new drug, EMB-001, combines metyrapone and oxazepam, both of which have been approved by the U.S. Food and Drug Administration. Embera NeuroTherapeutics, which has offices in Boston and Shreveport, will test its drug on about 24 smokers. Phase I trials determine whether a drug is safe to use and identify side effects, according to the National Institutes of Health.
Embera expects to complete the trial by the end of the year.
EMB-001 has been tested with promising results in a published pilot study on people with cocaine addictions, according to Embera.